Harmony Biosciences Launches Early Trial of Promising Orexin Agonist
PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has begun dosing participants in a Phase 1 clinical study of BP1.15205, a next-generation orexin 2 receptor agonist positioned as …
Harmony Biosciences Launches Early Trial of Promising Orexin Agonist Read More